Impel Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMPL research report →
About the company
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks.
- CEO
- Leonard S. Paolillo
- IPO
- 2021
- Employees
- 160
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $956.00K
- P/E
- -0.01
- P/S
- 0.08
- P/B
- -0.02
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
- Gross Margin
- 48.66%
- Op Margin
- -657.48%
- Net Margin
- -1023.08%
- ROE
- -3099.99%
- ROIC
- -122.46%
- Revenue
- $12.65M · 1794.01%
- Net Income
- $-129,440,000 · -69.12%
- EPS
- $-5.52 · -5.34%
- Op Income
- $-83,184,000
- FCF YoY
- -42.30%
- 52W High
- $4.20
- 52W Low
- $0.02
- 50D MA
- $0.34
- 200D MA
- $0.97
- Beta
- 1.17
- Avg Volume
- 1.02M
Get TickerSpark's AI analysis on IMPL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 18, 23 | Smith Brandon D | other | 0 |
| Dec 15, 23 | Vivo Capital VIII, LLC | sell | 87,934 |
| Dec 18, 23 | Vivo Capital VIII, LLC | sell | 209,029 |
| Dec 19, 23 | Vivo Capital VIII, LLC | sell | 208,657 |
| Dec 15, 23 | Vivo Capital VIII, LLC | sell | 12,066 |
| Dec 18, 23 | Vivo Capital VIII, LLC | sell | 28,682 |
| Dec 19, 23 | Vivo Capital VIII, LLC | sell | 28,632 |
| Nov 30, 23 | BROOKFIELD Corp /ON/ | other | 445,294 |
| Nov 30, 23 | Oaktree GCP Fund Delaware Holdings, L.P. | other | 445,294 |
| Nov 30, 23 | Oaktree-TCDRS Strategic Credit, LLC | other | 445,294 |
Our IMPL coverage
Recent articles, reports, and earnings notes.
No research on IMPL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMPL report →Similar companies
Peers in the same neighborhood.